Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index; 17 of the 49 sources its claims cite were checked for support.

Point-of-care testing: state-of-the art and perspectives

Open access

Abstract

Point-of-care testing (POCT) is becoming an increasingly popular way to perform laboratory tests closer to the patient. This option has several recognized advantages, such as accessibility, portability, speed, convenience, ease of use, ever-growing test panels, lower cumulative healthcare costs when used within appropriate clinical pathways, better patient empowerment and engagement, and reduction of certain pre-analytical errors, especially those related to specimen transportation. On the other hand, POCT also poses some limitations and risks, namely the risk of lower accuracy and reliability compared to traditional laboratory tests, quality control and connectivity issues, high dependence on operators (with varying levels of expertise or training), challenges related to patient data management, higher costs per individual test, regulatory and compliance issues such as the need for appropriate validation prior to clinical use (especially for rapid diagnostic tests; RDTs), as well as additional preanalytical sources of error that may remain undetected in this type of testing, which is usually based on whole blood samples (i.e., presence of interfering substances, clotting, hemolysis, etc.). There is no doubt that POCT is a breakthrough innovation in laboratory medicine, but the discussion on its appropriate use requires further debate and initiatives. This collective opinion paper, composed of abstracts of the lectures presented at the two-day expert meeting "Point-Of-Care-Testing: State of the Art and Perspective" (Venice, April 4-5, 2024), aims to provide a thoughtful overview of the state-of-the-art in POCT, its current applications, advantages and potential limitations, as well as some interesting reflections on the future perspectives of this particular field of laboratory medicine.

Overview

CoChat Summary

TL;DR

This collective opinion paper summarizes lectures from a 2024 Venice expert meeting on point-of-care testing (POCT), covering its advantages, limitations, applications, quality requirements, and future perspectives. It concludes that POCT is a breakthrough innovation but requires appropriate governance, quality systems, training, standardization, and better outcome/health-technology-assessment evidence.

Key findings

  • POCT offers accessibility, portability, speed, convenience, lower cumulative healthcare costs when used in appropriate clinical pathways, patient empowerment, and reduced specimen-transport preanalytical errors, but risks lower accuracy/reliability, quality-control and connectivity issues, operator dependence, data-management challenges, higher per-test costs, regulatory/compliance issues, and additional preanalytical errors such as interfering substances, clotting, and hemolysis.
  • Quality and accreditation: ISO 15189:2022 now includes POCT requirements from ISO 22870; for glucose POCT, positive patient identification (PPID) was a high-risk preanalytical indicator, with higher compliance where glucose meters were connected to the electronic health record; quality-control failures were mostly vial switches (33–72%); discordant critically high glucose results were linked to insufficient hand washing and line contamination.
  • Application-specific evidence: continuous glucose monitoring (CGM) is recommended for insulin-treated diabetes and has been associated with lower HbA1c and fewer hypoglycemic events; manual transcription of glycemia results was incorrect for time or concentration in approximately 3% of cases, with about 7% of those potentially leading to insulin dosing errors; hemoglobin excess differences >1 g/dL occurred in 1.43%; COVID-19 rapid antigen test sensitivity was 34.4%, improving to 55.3% on repeat and 68.5% on a third test, with specificity assumed 99.2% and prevalence boundaries of 7.37%, 10.46%, and 14.22% at a false omission rate of 5%; NRL evaluations found significant performance differences and 6 of 92 SARS-CoV-2 antigen RDTs non-compliant.
  • Value and networks: a review of 84 studies found 50% were correlation studies and only 13% evaluated impact on clinical practice; few health technology assessment reports exist and are often negative because they focus on analytical/preanalytical aspects; the Wales POCT network connected over 3,200 devices across 35 interfaces for a population of nearly 3.1 million.

Methods

  • Design: collective opinion paper composed of abstracts of lectures presented at the two-day expert meeting “Point-Of-Care-Testing: State of the Art and Perspective” (Venice, April 4–5, 2024), including a table summarizing the lectures.
  • Data or sample: no primary patient sample or systematic review; narrative overview of POCT state-of-the-art, current applications, advantages, limitations, and future perspectives across clinical settings and technologies.
  • Main analysis: narrative/opinion synthesis without a stated quantitative meta-analysis; research ethics and informed consent were not applicable, no funding was declared, and the authors state no conflicts of interest.

Limitations

  • Stated: there is a lack of complete, comprehensive, global evaluation of POCT impact; most studies report analytical performance rather than patient outcomes; clinical outcomes “have never been adequately evaluated”; randomized clinical trials and health technology assessment reports are compellingly needed; CGM lacks international acceptance criteria and study procedures, making performance comparisons difficult; POCT quality-assurance barriers include different sample types, cost/shipping/importation, lack of infrastructure, fixed test dates, and loss of QA data.
  • Stated: during COVID-19, Emergency Use Listing reduced performance-evidence requirements, more than 700 SARS-CoV-2 IVDs were available by June 2020, post-market assessment was generally not required, and “we are not ready to face a new pandemic.”
  • Evident: as an opinion paper based on meeting abstracts, it does not provide a systematic search, risk-of-bias assessment, or primary data; conclusions reflect expert perspectives and selected cited studies rather than a formal evidence synthesis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1515/cclm-2024-0675

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

11 Valid · 19 Not valid · 32 Not checked · 44 Own results and interpretations

32 more claims

Create a free account to see all 106 claims and to verify the 18 references still open.

See all claims — free account
  • It may state two separate claims as one. 50
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 32

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 70 references

Research works printed but not linked: 6

  1. Kost, GJ. Guidelines for point-of-care testing. Improving patient outcomes. Am J Clin Pathol 1995;104:S111–27.
  2. Hockman, B, Qi, M, Rotblatt, H. Overcoming analytical and preanalytical challenges associated with extra-genital home collected STI specimens. J Clin Microbiol. in press.
  3. International Medical Device Regulators Forum. Essential principles of safety and performance of medical devices and IVD medical devices, IMDRF good regulatory review practices group, Editor 2018. Available from: https://www.imdrf.org/documents/essential-principles-safety-and-performance-medical-devices-and-ivd-medical-devices [Accessed 24 May 2024].
  4. Fuzery, AK, Kost, GJ. Point-of-care testing by ambulance teams: an opportunity for a new standard. Clin Lab News 2021;47:8–13.
  5. National Institute for Health and Care Excellence. Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management. London: National Institute for Health and Care Excellence (NICE); 2023. (NICE Clinical Guidelines, No. 237) Available from https://www.ncbi.nlm.nih.gov/books/NBK598565/ [Accessed 8 May 2024].
  6. Kost, GJ. Changing diagnostic culture calls for point-of-care preparedness – multiplex now, open prevalence boundaries, and build community resilience. J 21st Century Pathol 2022;2:129.

Cited by

See all 119

Metadata

Authors
Plebani, M., Nichols, J. H., Luppa, P. B., Greene, D., Sciacovelli, L., Shaw, J., Khan, A. I., Carraro, P., Freckmann, G., Dimech, W., Zaninotto, M., Spannagl, M., Huggett, J., Kost, G. J., Trenti, T., Padoan, A., Thomas, A., Banfi, G., & Lippi, G.
Affiliations
  • University of Padua (IT)
  • Vanderbilt University Medical Center (US)
  • TUM Klinikum (DE)
  • University of Washington (US)
  • University of Ottawa (CA)
  • Temple University (US)
  • Department of Laboratory Medicine , Venice Hospital , Venice , Italy
  • Universität Ulm (DE)
  • National Serology Reference Laboratory , Melbourne , Australia
  • Institut für Laboratoriumsmedizin (DE)
  • LGC (GB)
  • University of California System (US)
  • Laboratory Medicine and Pathology Department AUSL e AOU Modena , Modena , Italy
  • National Health Service Wales (GB)
  • Vita-Salute San Raffaele University (IT)
  • University of Verona (IT)
Corresponding author
Plebani, Mario
Venue
Clinical Chemistry and Laboratory Medicine (CCLM)
Published
2024-06-17
Volume
63
Issue
1
Pages
35-51
ISSN
  • 1434-6621 (ISSN-L)
  • 1437-4331
OpenAlex
W4399756441
Cited by
119
References
70
Citations by year
2026: 69 · 2025: 46 · 2024: 4
FWCI
6.76
Type
journal article
Language
en
Open access
Locations
  • Clinical Chemistry and Laboratory Medicine (CCLM) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Topics
  • Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
  • Physical Sciences › Engineering › Biomedical Engineering › Biosensors and Analytical Detection
  • Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
Keywords
point-of-care testing, rapid diagnostic tests, pre-analytical errors, quality control, test validation, regulatory compliance, patient data management, whole blood samples, health care costs
MeSH terms
Point-of-Care Testing, Humans, Point-of-Care Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Point-of-care testing: state-of-the art and perspectives. https://app.cochat.ai/papers/10.1515/cclm-2024-0675
The paper
Plebani, M., Nichols, J. H., Luppa, P. B., Greene, D., Sciacovelli, L., Shaw, J., Khan, A. I., Carraro, P., Freckmann, G., Dimech, W., Zaninotto, M., Spannagl, M., Huggett, J., Kost, G. J., Trenti, T., Padoan, A., Thomas, A., Banfi, G., & Lippi, G. (2025). Point-of-care testing: state-of-the art and perspectives. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2024-0675

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.